Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

NCT05296564 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT05296564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Lead sponsor
Hadassah Medical Organization
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 1, 2022
Completion date
December 30, 2027
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, melanoma stage iv, metastatic cancer, neuroblastoma, metastatic, non small cell lung cancer, ovary cancer, sarcoma, synovial, sarcoma,soft tissue, triple negative breast cancer